Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Climb Bio, Inc. (CLYM)
Company Research
Source: GlobeNewswire
WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that Climb Bio has granted an inducement equity award to a new employee, pursuant to the Climb Bio’s 2025 Inducement Plan, as amended, as an inducement material to the new employee entering into employment with Climb Bio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on November 24, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of Climb Bio, which option has an exercise price of $1.76 per share, which is equal to the closing price per share of Climb Bio’s common stock as reported by The Nasdaq Global Market on November 24, 2025. In addition, the option has a ten-year term and vests over four years, with 25% of the original number of shares
Show less
Read more
Impact Snapshot
Event Time:
CLYM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CLYM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CLYM alerts
High impacting Climb Bio, Inc. news events
Weekly update
A roundup of the hottest topics
CLYM
News
- Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026GlobeNewswire
- H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks [Yahoo! Finance]Yahoo! Finance
- Here's Why We're Watching Climb Bio's (NASDAQ:CLYM) Cash Burn Situation [Yahoo! Finance]Yahoo! Finance
- Climb Bio (NASDAQ:CLYM) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
CLYM
Earnings
- 3/25/25 - Beat
CLYM
Analyst Actions
- 12/18/25 - HC Wainwright
CLYM
Sec Filings
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- 1/8/26 - Form 4
- CLYM's page on the SEC website